Lodge Martin A
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
J Nucl Med. 2017 Apr;58(4):523-532. doi: 10.2967/jnumed.116.186353. Epub 2017 Feb 23.
Quantitative analysis can potentially improve the accuracy and consistency of F-FDG PET, particularly for the assessment of tumor response to treatment. Although not without limitations, SUV has emerged as the predominant metric for tumor quantification with F-FDG PET. Growing literature suggests that the difference between SUVs measured before and after treatment can be used to predict tumor response at an early stage. SUV is, however, associated with multiple sources of variability, and to best use SUV for response assessment, an understanding of the repeatability of the technique is required. Test-retest studies involve repeated scanning of the same patient on the same scanner using the same protocol no more than a few days apart and provide basic information on the repeatability of the technique. Multiple test-retest studies have been performed to assess SUV repeatability, although a comparison of reports is complicated by the use of different methodologies and statistical metrics. This article reviews the available data, addressing issues such as different repeatability metrics, relative units, log transformation, and asymmetric limits of repeatability. When acquired with careful attention to protocol, tumor SUV has a within-subject coefficient of variation of approximately 10%. In a response assessment setting, SUV reductions of more than 25% and increases of more than 33% are unlikely to be due to measurement variability. Broader margins may be required for sites with less rigorous protocol compliance, but in general, SUV is a highly repeatable imaging biomarker that is ideally suited to monitoring tumor response to treatment in individual patients.
定量分析有可能提高F-FDG PET的准确性和一致性,特别是在评估肿瘤对治疗的反应方面。尽管并非没有局限性,但SUV已成为F-FDG PET肿瘤定量的主要指标。越来越多的文献表明,治疗前后测量的SUV差异可用于早期预测肿瘤反应。然而,SUV与多种变异性来源相关,为了最好地将SUV用于反应评估,需要了解该技术的可重复性。重测研究包括在不超过几天的时间内,使用相同的方案在同一台扫描仪上对同一患者进行重复扫描,并提供有关该技术可重复性的基本信息。已经进行了多项重测研究来评估SUV的可重复性,尽管由于使用了不同的方法和统计指标,报告的比较变得复杂。本文回顾了现有数据,讨论了不同的可重复性指标、相对单位、对数转换和不对称可重复性限度等问题。当在仔细遵循方案的情况下采集时,肿瘤SUV的受试者内变异系数约为10%。在反应评估环境中,SUV降低超过25%和升高超过33%不太可能是由于测量变异性。对于方案依从性较差的部位,可能需要更宽的界限,但总体而言,SUV是一种高度可重复的成像生物标志物,非常适合于监测个体患者的肿瘤对治疗的反应。